RHO and overactive bladder: As an effector protein of the small GTPase Rho, it is involved in the mechanism of action of antimuscarinic drugs, which are approved for the treatment of overactive bladder (OAB) and which clinical efficacy is driven by occupation at muscarinic M3 receptors, since Rho protein can be activated following M3 activation (Hegde 2006).